Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) involves immune cell signaling.
• Protein tyrosine kinase inhibitors target immune cell signal transduction.
• These inhibitors reduce pro-inflammatory cytokine production in RA.

Purpose of the Study:

• Review the role of Janus kinase (JAK), Bruton's tyrosine kinase (BTK), and spleen tyrosine kinase (SYK) inhibitors in RA treatment.
• Describe their mechanisms of action, rationale for use, and clinical trial outcomes.
• Provide expert opinion on current and future directions for these therapies.

Main Methods:

• Literature review of phase II and III clinical trials.
• Analysis of efficacy and safety data for kinase inhibitors in RA.
• Synthesis of expert opinion on clinical relevance and research needs.

Main Results:

• Bruton's kinase inhibitors development halted due to lack of superiority over placebo.
• Spleen kinase inhibitors deprioritized due to unfavorable risk/benefit profiles compared to JAK inhibitors.
• Janus kinase inhibitors demonstrated efficacy in treatment-naïve RA patients and those failing other therapies.

Conclusions:

• Janus kinase inhibitors are effective for rheumatoid arthritis.
• Further head-to-head trials are needed to assess JAK inhibitor selectivity.
• Long-term real-world studies are crucial to evaluate the safety profile of JAK inhibitors, focusing on malignancy and thromboembolic event risks.